Chordia Therapeutics Inc.

Direct answer

Chordia Therapeutics Inc. is publicly traded on JPX under the ticker 190A.T.

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc....

Can you invest in Chordia Therapeutics Inc.?

Yes. Chordia Therapeutics Inc. is publicly traded on JPX under the ticker 190A.T.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Chordia Therapeutics Inc.

Detailed equity research is provided by MarketSnap.